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Abstract: Cannabis use through smoking, vaping, or ingestion is increasing, but only limited studies
have investigated the resulting exposure to harmful chemicals. N-acetyl-S-(2-cyanoethyl)-L-cysteine
(2CYEMA), a urinary metabolite of acrylonitrile, a possible carcinogen, is elevated in the urine
of past-30-day cannabis users compared to non-cannabis users. Five frequent and five occasional
cannabis users smoked and vaped cannabis on separate days; one also consumed cannabis orally.
Urine samples were collected before and up to 72 h post dose and urinary 2CYEMA was quantified.
We compared 2CYEMA pre-exposure levels, maximum concentration, time at maximum concentration
for occasional versus frequent users following different exposure routes, and measured half-life of
elimination. Smoking cannabis joints rapidly (within 10 min) increased 2CYEMA in the urine of
occasional cannabis users, but not in frequent users. Urine 2CYEMA did not consistently increase
following vaping or ingestion in either study group. Cigarette smokers had high pre-exposure
concentrations of 2CYEMA. Following cannabis smoking, the half-lives of 2CYEMA ranged from 2.5
to 9.0 h. 2CYEMA is an effective biomarker of cannabis smoke exposure, including smoke from a
single cannabis joint, however, not from vaping or when consumed orally. When using 2CYEMA to
evaluate exposure in cannabis users, investigators should collect the details about tobacco smoking,
route of consumption, and time since last use as possible covariates.
Keywords: acrylonitrile; urine exposure biomarker; cannabis; exposure routes; half-life
1. Introduction
Although federal law does not allow its use, more and more states are legalizing the retail
non-medical adult use of cannabis (most commonly known as marijuana) [1,2]. Cannabis use peaked in
the late 1970s, declined until the early 1990s, but has been rising over the last 30 years [3]. Between 2006
and 2017, the annual prevalence of cannabis use in the 19–28 age group increased from 27.7% to 37.5%
and for those age 35, from 11.4% to 23.8%. Daily marijuana use in the 19–28 age group increased from
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5.0% in 2006 to 7.8% in 2017 and for those age 35 from 1.9% in 2006 to 5.1% in 2017 [3]. Even though
edibles and vaping are substantial routes of use by adolescents, smoking is still the most frequent
means of consuming cannabis [4–6]. With legalization, adults and adolescents increasingly view
cannabis consumption as harmless [7,8]. As use increases, public health issues such as driving while
intoxicated, fatal car crashes [9], unintentional ingestion of cannabis products by children, worsening
cognition and psychosis [10], increased exposure to secondhand smoke, and health problems including
dependence and respiratory disorders [1,8,11,12] are becoming critically important. However, there is
a lack of rigorous, quality data on health outcomes from cannabis use, both alone and when combined
with tobacco [13]. Recently, laboratory data have shown that Vitamin E acetate, a component in
some ∆9-tetrahydrocannabinol (THC) e-cigarette or vaping products, has been associated with an
E-cigarette and Vaping Lung Injury (EVALI) outbreak [14]. Before the growing use of cannabis becomes
a substantial public health issue, research is needed to better understand the health impact of its use
and to inform state and federal regulatory agencies, health organizations, and health care professionals,
so that appropriate action can be taken [1,11].
Only a limited amount of studies examined the concentrations of harmful and potentially harmful
constituents in cannabis smoke. Polycyclic aromatic hydrocarbons (PAHs) are generated by the burning
of organic matter and are in cannabis smoke [15,16]. PAH concentrations with molecular weight greater
than that of chrysene increased significantly in cannabis as compared to tobacco smoke, suggesting
an increased cancer risk. In contrast, others reported that PAHs were lower in cannabis smoke [17].
Investigators also reported that nitrogen-containing compounds, including acrylonitrile, ammonia,
hydrogen cyanide, NO, NOx, and aromatic amines, were higher in cannabis smoke than in tobacco
smoke and, in contrast, formaldehyde and acetaldehyde were lower [17,18]. Rickert et al. [19] found
that smoking one cannabis joint compared to smoking one manufactured tobacco cigarette yielded
higher levels of “tar”, higher pH, and about the same carbon monoxide (CO) under “realistic” smoking
conditions: 70 mL puff volume, 5 sec puff duration, and 30 sec puff interval. On a per puff basis,
manufactured cigarettes delivered about twice the CO but a similar amount of “tar” as a cannabis joint.
Many studies identified and quantified harmful and potentially harmful constituent (HPHC)
biomarker concentrations in cigarette smokers’ urine, including acrylonitrile [20]. However,
few investigations evaluated the harmful constituents, besides THC and its metabolites, in blood
or urine following cannabis use [21]. Wu et al. [22] concluded that smoking cannabis, regardless of
THC content, results in a substantially greater respiratory burden of carbon monoxide and tar than
smoking a similar quantity of tobacco. Biomarkers of exposure to cannabis smoke were compared
between users and non-users using data from the National Health and Nutrition Examination Survey
(NHANES) [23]. In this study, concentrations of many metabolites of individual monohydroxy PAHs,
thiocyanate, acrylonitrile, and acrylamide increased in the urine of recent cannabis users compared to
non-users. Smith et al. [24] examined biomarkers of exposure to nicotine, tobacco-specific nitrosamines,
volatile organic compounds, and PAHs and determined that, among non-tobacco products users, only
urinary N-acetyl-S-(2-cyanoethyl)-L-cysteine (a biomarker of acrylonitrile) concentrations were elevated
in past-30-day cannabis users compared to non-cannabis users. The International Agency for Research
on Cancer (IARC) determined that acrylonitrile is possibly carcinogenic to humans (class 2B) and may
present a particular exposure concern for cannabis users because of its possible carcinogenicity and
high concentration in cannabis smoke compared to cigarette smoke [19,25]. Breath-holding in cannabis
smokers was found to be associated with increased blood carboxyhemoglobin, inhaled and deposited
tar, serum THC, and subjective effects in controlled topography exposures [26]. Non-THC-related
constituent exposure is important to include in any assessment of possible harm from cannabis use.
Previous studies on non-THC-related exposure were limited in scope and applicability, so that there
remains significant uncertainty on the likelihood that these ancillary exposures present a substantial
source of risk to users. In the most relevant previous studies described above, investigators examined
acrylonitrile urinary metabolites in cannabis users [23,24]. However, the length of time between
use and sample collection were nonspecific, asking only whether participants used cannabis that
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day. Subjects were not asked about recency of last use, frequency of use, or what product they used.
Subjects may have been exposed to other sources of acrylonitrile exposure that were not adequately
addressed in the exposure questions. The study by Wei et al. [23] used modeling to remove the
contribution of cigarette smoking and, while useful, this approach may not have adequately addressed
this confounder.
In order to assess the health risk from cannabis use, we need to know the levels of
acrylonitrile exposure from a single cannabis use, which routes increase exposure, and whether
the acrylonitrile exposure is limited to combustion. Understanding the time dependence of
urinary excretion of acrylonitrile exposure biomarkers would inform sample collection and inform
interpretation of results [27]. This research examined creatinine-corrected urinary concentrations
of N-acetyl-S-(2-cyanoethyl)-L-cysteine (2CYEMA), a major metabolite of acrylonitrile [28],
over approximately 48 h following controlled smoked, vaped, and oral cannabis administration
of 50 mg THC in occasional and frequent cannabis users.
2. Materials and Methods
2.1. Study Design
The study was a within-subject, randomized, double-blind, double-dummy, and placebo-controlled
investigation, with each participant consuming products that contained 50 mg THC by three different
routes of administration, and a placebo. The primary objectives of the study were to evaluate cannabinoid
pharmacokinetics and pharmacodynamics following different administration routes in chronic frequent
and occasional cannabis users. Detailed descriptions were published previously [29,30] and are
summarized below. Additional biomarkers of cannabis exposure were measured as secondary targets
and have been reported previously [29].
2.2. Subjects
The ten participants in the additional biomarker exposure study were healthy adult volunteers
aged 18 to 50 years, who provided informed written consent to participate. The study was approved by
Institutional Review Boards of the National Institute on Drug Abuse, Food and Drug Administration,
and the Drug Enforcement Administration. Details on the subjects, inclusion and exclusion criteria,
and confinement have been provided previously [28]. Subjects were included if they self-reported
a mean cannabis intake frequency ≥2 per month but ≤3 per week (occasional users) or ≥5 per week
(frequent users) over the previous 3 months and had a positive urine cannabinoid screen (frequent
users). Participants entered the secure research unit approximately 19 h before controlled cannabis
administration and resided there throughout the study to eliminate exposure to cannabis, but subjects
were allowed to smoke tobacco cigarettes during this period.
2.3. Exposures and Sample Collection
Cannabis cigarettes, which are rolled like a joint and do not include a filter, were acquired from
the National Institute on Drug Abuse Drug Supply Program. Active cannabis cigarettes weighed
0.734 ± 0.05 g and contained 6.9% (0.95%) (approximately 50.6 mg) THC. Placebo cigarettes weighed
0.713 ± 0.05 g and contained 0.001% (0.000%) THC. The Volcano© Medic (Vapormed GmbH and
Co., Tuttlingen, Germany) vaporizer was used for vaping of cannabis and operated according to the
manufacturer’s specifications. THC vapor was produced using plant material from one 6.9% THC
cigarette, ground using an herb mill/grinder provided by the Volcano manufacturer, and heated to a
temperature of 210 ◦C by the hot air generator to vaporize THC. The vapor was collected in a plastic
balloon attached to a mouthpiece that allowed the subject to control inhalation. Each session utilized
a new balloon to ensure hygienic administration. Cannabis brownies were prepared with the same
cannabis material as smoking and vaping. Each brownie contained 50.6 mg THC. Plant material
was ground to a fine powder before addition to the Duncan Hines® double-fudge brownie mix,
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which was then prepared according to the manufacturer’s instructions and baked for 30 min at 121 ◦C.
Each portion contained the equivalent of one cigarette. After baking and cooling, the brownie portions
were frozen until use. The portion was removed the night before administration and allowed to thaw
in a refrigerator overnight.
During each of the four sessions, one of the three active doses of cannabis or the placebo was
administered. The order of administration was random. Subjects were instructed to consume as
much as they could from the dose and were encouraged to consume the entire dose within 10 min.
Urine samples were collected before and up to 54 h post dose for occasional smokers and up to 72 h post
dose for frequent smokers. Participants collected all voided urine ad libitum as individual specimens in
polypropylene bottles throughout their stay in the unit. Specimens were refrigerated until checked for
total volume, pH, specific gravity, and creatinine. Aliquots were stored frozen at −20 ◦C until analysis
for acrylonitrile biomarkers. Subjects were required to leave the unit for ≥72 h before the next session.
2.4. 2CYEMA Analysis
Urinary 2CYEMA was quantified by ultrahigh-performance liquid chromatography coupled with
electrospray ionization tandem mass spectrometry with a calibration range of 0.05–150 ng/mL and a
detection limit of 0.50 ng/mL, as previously described [31]. To account for differences in urine dilution,
values were creatinine-corrected. Urine samples with creatinine concentrations outside the range of
10–500 mg/dL were rejected. This resulted in the rejection of two results. One other result was an
evident outlier and rejected; 2CYEMA (18.4 µg/g creatinine, 9 times higher than expected based on
data at times immediately before and after, 2.1 and 1.9 µg/g creatinine), THC-glucuronide (detectable
whereas points before and after were not detectable), and THCCOOH-glucuronide (3 times higher than
expected based on data at times immediately before and after) were all much higher than expected.
Urinary cotinine was determined as described previously [32]. The urinary nicotine cutoff for cigarette
smoker versus non-smoker was 50 ng/mL [33].
2.5. Statistical Analysis
Simple data manipulation and analyses were performed in Microsoft Excel for Office 365.
Nonlinear regression analysis of 2CYEMA versus time was accomplished in SAS version 9.4 PROC
NLIN using the equation:
2CYEMA (corrected) = a ∗ (exp(−time/c)) + b (1)
where a is the time 0 increase above baseline (µg/g creatinine), b is the baseline (estimated level at
infinite time, µg/g creatinine), and c is the half-life (h).
3. Results
Figure 1A shows the change in 2CYEMA over time before and after smoking one cannabis joint
by an occasional cannabis user. For this subject, 2CYEMA increased immediately after use and reached
a maximum concentration of approximately 8.2 µg/g creatinine about 7 h after the start of smoking.
Over the next 30 h, 2CYEMA decreased until reaching a baseline of approximately 1.2 µg/g creatinine.
Conversely, immediately after this same occasional cannabis user vaped cannabis, 2CYEMA did not
increase (Figure 1B). The data show a maximum 2CYEMA concentration at 13 h and a slow decrease
in 2CYEMA over the next 30 h. 2CYEMA concentrations over time before and after ingestion of a
cannabis brownie by this same occasional cannabis user did not change substantially (Figure 1C).
On two different days, each cannabis user smoked a single cannabis joint or vaped an equivalent
amount of cannabis in 10 min. Table 1 provides 2CYEMA for the sample collected at the time
immediately before product use, the maximum 2CYEMA achieved following initiation of product use
(Cmax), and time to reach maximum 2CYEMA (Tmax) for all 10 subjects. In most cases, the maximum
occurred within 4 h of the initiation of cannabis use. In some cases, there was not a rapid increase
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in 2CYEMA following use or a clear decrease after exposure ended; the maximum value may have
occurred later.Int. J. Environ. Res. Public Health 2020, 17, x 5 of 11 
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Figure 1. Creatinine-corrected urine 2CYEMA (µg/g creatinine) concentrations over time before and
after smoking of a cannabis joint (A) vaping of cannabis (B) or ingestion of a cannabis brownie (C) by
an occasional cannabis user.
Pre-exposure 2CYEMA in occasional cannabis users ranged from 0.84 to 29.2 µg/g creatinine.
Following smoking a cannabis joint, these concentrations increased to between 8.2 and 69.0 µg/g
creatinine, an increase ranging from 4.1 to 39.8 µg/g creatinine, or a percent increase from pre-exposure
to maximum concentration for each subject ranging from 55.4% to 1570%. When these subjects vaped
cannabis, the pre-exposure 2CYEMA was similar (1.1–15.5 µg/g creatinine). However, post exposure
2CYEMA concentrations increased only to 1.5–15.6 µg/g creatinine. The differences in 2CYEMA
before and after exposure ranged from −0.4 (all post exposure concentrations were lower than the
pre-exposure concentrations) to 1.2 µg/g creatinine and the percent increases ranged from −12.5% to
75.0%. For comparison, the pre-exposure concentration was 1.2 µg/g creatinine and the Cmax post
exposure concentration was 2.3 µg/g creatinine with a Tmax of 11.6 h for subject K when consuming the
THC-containing brownie.
For frequent cannabis users, the pre-exposure 2CYEMA before smoking a joint was between 23.3
and 204 µg/g creatinine and showed a wide range of differences post exposure (−38.0 to 86.1 µg/g
creatinine, −35.6% to 149%). For the two subjects with the highest pre-exposure 2CYEMA, no post
exposure 2CYEMA was greater than the pre-exposure level. The difference between the post exposure
maximum 2CYEMA and the pre-exposure 2CYEMA for frequent cannabis users following cannabis
vaping ranged from −26 to 1.5 µg/g creatinine (−36.0% to 6.4%). No substantial increases in 2CYEMA
were se n in any of these five subjects under these conditions.
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Table 1. Creatinine-corrected urinary 2CYEMA concentrations in occasional and frequent cannabis users
immediately before product use, maximum concentrations (Cmax), and time to maximum concentration
(Tmax) following product use.
Subject
Smoked Cannabis Vaped Cannabis
Pre-Exposure Cmax Post Exposure(µg/g Creatinine)
%






K 1.7 8.2 382 7.1 2.0 3.2 60.0 12.8
P * 29.2 69.0 136 2.2 15.5 15.6 0.6 0.7
U 7.4 11.5 55.4 2.4 1.1 1.5 36.4 9.8
W 3.5 23.7 577 3.8 3.2 2.8 −12.5 5.0
X 0.84 14.0 1570 1.2 1.2 2.1 75.0 3.9
Frequent Users
D * 23.3 30.0 28.8 3.8 34.2 34.7 1.5 2.4
G * 65.2 42.0 −35.6 6.6 44.5 28.5 −36.0 20.0
L * 25.9 52.0 101 3.8 26.6 24.3 −8.6 1.2
T * 204 166 −18.6 0.4 140 114 −18.6 0.6
Y * 57.9 144 148 1.3 23.4 24.9 6.4 3.1
* Cigarette Smoker.
Urinary cotinine differentiated cigarette smokers and non-smokers among the ten subjects.
All frequent cannabis users were also cigarette smokers. Pre-exposure 2CYEMA in the four non-cigarette
smokers ranged from 0.84 to 7.4 µg/g creatinine. Pre-exposure 2CYEMA in the six cigarette smokers
ranged from 23.3 to 204 µg/g creatinine. Pre-exposure 2CYEMA was higher in the cigarette smokers,
including the one occasional cannabis user, than the range of 2CYEMA in non-cigarette smokers,
despite the 19 h cannabis washout period; participants were permitted to smoke cigarettes during the
non-protocol pre-exposure period, which likely contributed to variation in the initial 2CYEMA.
Figure 2 shows a nonlinear exponential fit of 2CYEMA versus time after the beginning of smoking
cannabis for subject X. The data are well characterized by the nonlinear curve and yield a 2CYEMA
increase above baseline at time 0 of 14.9 µg/g creatinine, a baseline of 1.7 µg/g creatinine, and a half-life
of 3.9 h. Uncertainty in the data does not preclude the possibility of more complex excretion kinetics.
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Figure 2. Post exposure creatinine-corrected urine 2CYEMA (µg/g creatinine) over time following
smoking of a cannabis joint by an occasional cannabis user with a best-fit exponential curve.
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Table 2 shows the results of the nonlinear exponential fit of 2CYEMA versus time after the
beginning of exposure for both occasional and frequent cannabis users. The data for subject D failed
to converge and the nonlinear exponential fits for subject L and T were not statistically significant.
In agreement with the data provided in Table 1, both baseline and 2CYEMA at time 0 above baseline
for non-tobacco smoking occasional cannabis users were lower than the range of frequent users and/or
cigarette smokers.
Table 2. Results of the nonlinear exponential fit of creatinine-corrected urinary 2CYEMA concentrations
(µg/g creatinine) versus time after the beginning of product use.




(h) Pr > F
K 23.2 1.4 6.0 0.0005
P * 101 19.8 3.1 <0.0001
U 13.0 2.3 9.0 0.0001
W 32.9 3.1 7.4 <0.0001
X 14.9 1.7 3.8 <0.0001
Frequent Users
D * Did not converge **
G * 163 25.0 3.9 0.020
L * 33.0 26.8 10.1 0.14
T * 87.4 93.0 2.5 0.30
Y * 309 33.4 2.5 0.0007
* Cigarette Smoker. ** Nonlinear regression analysis could not reach a minimum sum of squared residuals for
the model.
4. Discussion
These results demonstrate that urinary 2CYEMA increases rapidly in non-smoking occasional
cannabis users. The quantitative increase in 2CYEMA in this subset of participants was fairly consistent,
ranging from 4.1 to 20.2 µg/g creatinine. Because users were free to smoke cannabis as intensely as
they chose in the 10 min period, it is likely that the range of 2CYEMA increases results from differences
in smoking topography. Peak nicotine concentrations in users of e-cigarettes vary considerably due
to smoking behavior [34,35] and similar factors are likely affecting the 2CYEMA results in this study.
Wei et al. [23] previously reported the geometric means of 2CYEMA in the urine of non-users of tobacco
(1.44 (95%CI: 1.34, 1.56) ng/mL), cannabis users (15.4 (95%CI: 8.15, 29.0) ng/mL), and cigarette smokers
(24.0 (95%CI: 15.0, 38.5) ng/mL). If one assumes an average creatinine concentration of 100 mg/dL for the
results from Wei’s study [24], our pre-exposure results for non-smoking occasional cannabis users were
generally between their reported biomarker concentrations for 2CYEMA in non-users of either tobacco
or cannabis and cannabis users. Post exposure maximums for our non-smoking occasional cannabis
users are within their reported range of 2CYEMA in cannabis users [23]. Post exposure maximum
2CYEMA for frequent cannabis users (who were also tobacco cigarette smokers) are similar or higher
than their results. This is as expected since, in our study, these subjects were all dual cannabis/cigarette
users and samples were collected immediately after cannabis use.
Vaping cannabis did not consistently increase 2CYEMA across users and the differences between
pre- and post exposure 2CYEMA were small and unpredictable. For several of the subjects, including
one occasional user, 2CYEMA immediately before vaping was higher than any 2CYEMA results
following use. This suggests that, in contrast to cannabis joint smoking, vaping cannabis does not lead
to substantial exposure to emissions of acrylonitrile from a single bout. Since vaping heats cannabis
at a lower temperature than smoking either cannabis or tobacco cigarettes, acrylonitrile may not be
generated or volatilized and released into the inhaled aerosol at this lower temperature. While there
are numerous harmful and potentially harmful constituents (HPHCs) generated in cannabis smoke,
higher concentrations of acrylonitrile in combusted cannabis smoke compared to non-combusted
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cannabis aerosol may suggest an additional cancer risk, even though its harm relative to other HPHCs
is undetermined at this time.
Smoking cannabis joints significantly increased 2CYEMA in the urine of occasional cannabis
users. However, in frequent cannabis users, the difference between post and pre-exposure 2CYEMA
was not consistently positive. This is likely due to confounding from tobacco smoking during the
pre-protocol period, since all frequent cannabis users were also tobacco cigarette smokers. The three
frequent cannabis use participants with lower pre-exposure 2CYEMA did show a measurable increase
following cannabis smoking. However, for the two participants with higher pre-exposure 2CYEMA,
the pre-exposure concentration was higher than any of the post exposure concentrations. This may
also be related to differences in product use behavior, since more intense smoking should lead to higher
biomarkers of exposure. However, analysis of the relationship between THCCOOH-glucuronide and
2CYEMA post exposure for all subjects did not show a statistically significant association as would
have been expected if intensity of use were a dominant factor.
For the seven subjects with 2CYEMA data after cannabis smoking that could be successfully fit
to a nonlinear exponential, the half-lives ranged from 2.5 to 9.0 h. Jakubowski et al. [36] examined
2CYEMA excretion kinetics in six participants following 8 h of acrylonitrile exposure by inhalation of
gas generated in an exposure chamber for up to 31 h after exposure with no known other sources of
exposure. In their investigation, elimination approximated first-order kinetics and had a mean half-life
of approximately 8 h, within the range determined in our study. The higher mean half-life determined
by Jakubowski in comparison to much of our data may have been due to the different times of exposure
and the previously unexposed nature of the study subjects. Increasing exposure time in their study
may have allowed deposition into deeper body stores that would require a longer time for elimination.
Goniewicz et al. [27] examined the half-life of 4-(methylnitrosamino)-1(-3-pyridyl)-1-butanol
(NNAL), the metabolite of a known carcinogen in tobacco smoke, in the urine of eight daily (>15 per day)
and five occasional tobacco smokers (<20 per month). They found that the non-compartmental
half-life for daily cigarette smokers was 9.1 days and for occasional cigarette smokers, 16.0 days.
The investigators suggested the difference between occasional and frequent cigarette smokers was
deposition in deep tissue compartments with a long terminal half-life. Although the half-lives were
different for the two chemicals studied, we found a similar result in our data, since the half-lives of
2CYEMA in frequent cannabis users/cigarette smokers ranged from 2.5 to 3.1 h whereas the half-lives
of 2CYEMA in occasional cannabis users ranged from 3.8 to 9.0 h. The data in Figure 2 suggest
that the elimination kinetics may be multiexponential, but the data collected here were not adequate
to make this determination for most of the participants. Boogaard and van Sittert [37] reported
that the half-life of S-phenyl mercapturic acid, a metabolite of the tobacco smoke-related volatile
organic compound, benzene, following inhalation was 9.1 ± 0.7 (SE) h, which is in line with our
findings. Fuhr et al. [38] examined the elimination kinetics of mercapturic metabolites of acrylamide
after ingestion. The half-life of N-acetyl-S-(2-carbamoylethyl) cysteine was 17.4 ± 3.9 (SD) h and for
N-acetyl-S-(2-hydroxy-2-carbamoylethyl) cysteine, 25.1 ± 6.4 (SD) h. However, elimination following
ingestion would be longer due to the time required for absorption in the gastrointestinal tract.
The study was strengthened by the confinement of subjects and use of cannabis in a controlled
setting. The collection of all urine samples up to 54–72 h post dose (at least six half-lives) allowed
for better determination of the baseline 2CYEMA, which helps in modeling elimination kinetics and
half-life determination. The use of products with the same amount of THC and over the same time
period allowed a direct comparison between routes of exposure and between subjects.
However, there were limitations to this study. The urine elimination of 2CYEMA was examined
in only ten participants in this study, limiting the generalizability of the findings. While this study
evaluated three different routes of consumption, it examined only a single amount of cannabis, 50 mg.
Other levels, either higher or lower, could lead to different results, particularly relative to the amount
of acrylonitrile to which cigarette smokers are exposed. The use behavior of the products was only
restricted by a maximum amount of time, during which subjects were required to consume the
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products, but this could also be considered a strength since this was natural instead of controlled use.
If participants smoked the entire joint in 4 min, the rate of increase and maximum 2CYEMA attained
may differ substantially from a subject who used the entire 10 min period to consume the product.
Most of the subjects were tobacco smokers and acrylonitrile is present in cigarette smoke. Because
all frequent cannabis users were also cigarette smokers, we cannot differentiate these two sources of
confounding. The pre-exposure levels of 2CYEMA in many cases were not low, even after 19 h of THC
washout, likely because participants were allowed to smoke tobacco during the pre-exposure period.
High initial 2CYEMA may have obscured increases in 2CYEMA in participants who smoked tobacco
when vaping cannabis.
5. Conclusions
By collecting and analyzing 2CYEMA in samples collected before and after smoking, vaping,
or eating cannabis, the study showed that smoking a cannabis joint markedly increases 2CYEMA
within 10 min in occasional users. Vaping or eating cannabis does not appear to alter 2CYEMA
levels substantially. However, the boiling point of acrylonitrile is 77.3 ◦C, so the acrylonitrile may
have no longer been present when consumed in brownies. Therefore, acrylonitrile either must be a
combustion product of cannabis use or released from the cannabis during the elevated temperatures
encountered during combustion. The half-lives of 2CYEMA range from 2.5 to 9 h and vary depending
on previous exposure to acrylonitrile, perhaps through frequent smoking of tobacco or cannabis use.
In order to interpret exposure accurately in cannabis smokers using 2CYEMA, details about tobacco
smoking and the time since last use of cannabis should be collected and included as a covariate in any
subsequent analysis.
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